Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.

@article{Chapman1987ClinicalPO,
  title={Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.},
  author={Paul B Chapman and T J Lester and Ephraim S. Casper and Janice L. Gabrilove and Gilbert Y. Wong and Sanford Jay Kempin and Philip Jordan Gold and Sydney Welt and Robert S. Warren and H F Starnes},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1987},
  volume={5 12},
  pages={1942-51}
}
Twenty-six patients with advanced cancer refractory to standard therapy were treated with recombinant human tumor necrosis factor (rTNF) in a study aimed at determining the toxicity and tolerance of rTNF and at seeking evidence of antitumor activity. The study design involved two treatments per week for 4 weeks with alternating subcutaneous and intravenous (IV) administration, and weekly dose escalation through four levels in each patient. The dose range was 1 to 200 micrograms/m2 for IV bolus… CONTINUE READING